| Homepage | Forward to a Friend | Make a Donation |
 |
| eLetter #722 | August 4, 2017 |
|
 Scleroderma and SSC Research Funded by Rheumatology Research Foundation
The
following three grant awards were recently funded by the Rheumatology
Research Foundation. Follow the link below to read summaries of
the studies.
- Interleukin-13 and Scleroderma in African Americans, Nadia D. Morgan, M.B.B.S., Johns Hopkins University
- Lysophospatidic Acid as a Biomarker in Systemic Sclerosis, Sara R. Schoenfeld, M.D., Massachusetts General Hospital
- Discovering Predictors of Treatment Response in Scleroderma Lung Disease, Elizabeth R. Volkmann, M.D., M.S., University of California, Los Angeles
Read more
|
15th International Workshop on Scleroderma Research, August 5-9, 2017
The International Workshop on Scleroderma Research is a four-day research meeting centered on translational medicine related to systemic
sclerosis which is organized and executed by the University of Pittsburgh
Division of Rheumatology and Clinical Immunology and the Centre for
Rheumatology and Connective Tissue Disorders at University College London
(Royal Free Hospital Campus), in association with Boston University School of
Medicine. The meeting covers areas key to making advances in clinical research
in systemic sclerosis and is typically attended and presented by thought
leaders in associated complications.
Read more
|
Inventiva to Present New Data on IVA337 at the 15th International Workshop on Scleroderma Research in Pittsburgh, Penn.
Read this summary of their abstract, which was hailed as one
of the best papers in the upcoming workshop.
|
|
 Gluten-Free Diet Food Label Reading Guide
The Celiac Disease
Foundation publishes a very helpful guide on reading food labels to identify
gluten-free foods and to avoid foods with gluten products, including hidden
sources and cross-contact.
Read more
|
|
Pulmonary Fibrosis in Connective Tissue Disease (CTD): Urgent Challenges and Opportunities
Read this insightful article by Aryeh Fischer, M.D., a member
of the Scleroderma Foundation’s National Medical and Scientific Advisory Board.
|
| Clinical Trial News |
|
Cytori Releases Preliminary Data from STAR Trial
Cytori Therapeutics announced on July 24 the top-line 24- and 48-week
results from the STAR trial of Habeo™ Cell Therapy in patients with scleroderma. While statistical significance was not achieved in the
primary or secondary endpoints, clinically
meaningful trends were observed in the pre-specified diffuse cutaneous
scleroderma subgroup.
Read more
|
|
|
|
|
Disclaimer: The Scleroderma Foundation in no way
endorses any drugs, treatments, clinical trials, or studies reported in the eLetter. Information is
provided to keep the readers informed. Because the manifestations and severity of scleroderma vary among individuals, personalized medical management is essential. Therefore, it is strongly recommended that all drugs and treatments be discussed with the reader’s physician(s) for proper evaluation and treatment.
|
 |
|
